 we are off to a strong start in 2021 with strong top and bottom line performance across our therapeutic portfolio. in neuroscience, revenues were more than $1.2 billion, up 10.9% on a comparable operational basis. our immunology portfolio delivered global revenues of more than $5.7 billion, reflecting growth of nearly 12% on an operational basis. Humira sales were approximately $4.9 billion, up 5.2% on a comparable operational basis excluding a 1.1% favorable impact from foreign exchange. 
 we continue to see robust sales from our key and newly launched products. Skyrizi and Rinvoq contributed nearly $900 million in combined revenues this quarter, more than double the sales versus the prior year as both products continue to ramp in their initial indications. 
 Imbruvica and Venclexta delivered combined sales of approximately $1.7 billion, reflecting continued growth in hematological oncology and other malignancies. 
 we also saw double-digit comparable growth from Linzess, the leading branded prescription medicine in the U.S. for the treatment of adults with idiopathic constipation. 
 we continue to see robust growth from our new immunology agents, Skyri